Black Rock Inc. F Star Therapeutics, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$4.09 - $6.86 $1,513 - $2,538	-370 Reduced 0.12%	297,433 $1.88 Million
Q3 2022 Nov 14, 2022	BUY	$5.41 - $6.74 $5,139 - $6,403	950 Added 0.32%	297,803 $1.52 Million
Q2 2022 Aug 12, 2022	BUY	$2.18 - $6.39 $1,975 - $5,789	906 Added 0.31%	296,853 $1.86 Million
Q1 2022 May 12, 2022	BUY	$2.77 - $5.36 $13,229 - $25,599	4,776 Added 1.64%	295,947 $1.05 Million
Q4 2021 Feb 10, 2022	BUY	$4.71 - $7.38 $8,397 - $13,158	1,783 Added 0.62%	291,171 $1.46 Million
Q3 2021 Nov 09, 2021	BUY	$5.2 - $8.42 $3,317 - $5,371	638 Added 0.22%	289,388 $2.12 Million
Q2 2021 Aug 11, 2021	BUY	$6.57 - $10.71 $1.9 Million - $3.09 Million	288,750 New	288,750 $2.48 Million

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.